QL Biopharm Presented Results from Phase 1c Clinical Study on its Novel Once-Monthly GLP-1RA ZT002 at EASD 2024 ...Middle East

– ZT002 was safe and well tolerated in both biweekly and monthly dosing arms in patients with overweight or obesity with a tolerability profile aligned with the GLP-1RA class – The open-label extension with ZT002 120 mg, once-monthly, showed 17.1% reduction in body weight at 30 weeks...

Hence then, the article about ql biopharm presented results from phase 1c clinical study on its novel once monthly glp 1ra zt002 at easd 2024 was published today ( Thursday 12/09/2024 - 12:22 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( QL Biopharm Presented Results from Phase 1c Clinical Study on its Novel Once-Monthly GLP-1RA ZT002 at EASD 2024 )

Also on site :

• Inside the chaos at Canoo, the zero-revenue, cash-burning EV company that just inked a major deal with Walmart
• Zelensky’s inner circle accused of war profiteering
• Norway’s fish farm waste ‘triple the country’s sewage’ – report